Last update 01 Jun 2024

Luxdegalutamide

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras
Synonyms
ARV 766, ARV-766, ARV766
Target
Mechanism
AR antagonists(Androgen Receptor antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC45H54FN7O6
InChIKeyRDPPBRKNBBXPNZ-FMPIRMQTSA-N
CAS Registry2750830-09-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prostatic cancer metastaticPhase 2
US
02 Sep 2021
Prostatic CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
103
iuawoayvuq(cfqrnmpfpq) = Any grade treatment-related adverse events (TRAEs) reported in ≥10% of patients were fatigue (36%; 3% grade 3), nausea (19%; 1% grade 3), diarrhea (15%; 1% grade 3), alopecia (14%), increased blood creatinine (13%; 0 grade 3), and decreased appetite (11%; 0 grade 3); there were no grade 4 TRAEs qqioxjjskb (kzhszdhkhn )
Positive
24 May 2024
Phase 1/2
-
(AR LBD mutation)
kmfuoeljmd(aurejsiksl) = adcvuymapf xyekobptca (iknlctuxva )
Positive
22 Oct 2023
(AR L702H mutation)
kmfuoeljmd(aurejsiksl) = hepfzbfkyr xyekobptca (iknlctuxva )
Phase 1/2
-
uotilsitxk(znzfuogaff) = bqsehrtewr mlrbkowmcj (hfarovnesy )
Positive
08 Aug 2023
(AR LBD mutations)
svkaqufaal(befhhmyuqn) = cwsuantlkc pkujammlaf (tiyqqlnfld )
Phase 1/2
-
ojvkczdvaz(akcncqcdcw) = ARV-766 has been well tolerated and the majority of treatment-related adverse events (TRAEs) have been Grade 1 or 2, with no Grade ≥4 TRAEs and no dose limiting toxicities bcvqofpmcx (raomipryey )
Positive
08 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free